AnaptysBio’s (ANAB) Buy Rating Reiterated at UBS Group

UBS Group reiterated their buy rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note released on Wednesday morning, MarketBeat.com reports. The brokerage currently has a $70.00 target price on the biotechnology company’s stock, up from their previous target price of $20.00.

A number of other equities analysts have also recently commented on ANAB. Truist Financial raised their target price on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Barclays decreased their price objective on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, October 8th. HC Wainwright dropped their price target on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Monday, November 24th. Finally, Wedbush reissued an “outperform” rating and issued a $50.00 price objective on shares of AnaptysBio in a research note on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $60.40.

AnaptysBio Trading Up 2.0%

ANAB opened at $44.67 on Wednesday. The company’s 50 day moving average is $42.62 and its 200 day moving average is $31.46. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -15.84 and a beta of 0.32. AnaptysBio has a 12-month low of $12.21 and a 12-month high of $52.47.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. The business had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. As a group, analysts predict that AnaptysBio will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its Board of Directors has initiated a share repurchase plan on Friday, November 21st that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at AnaptysBio

In related news, CFO Dennis Mulroy sold 15,725 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $44.85, for a total transaction of $705,266.25. Following the completion of the transaction, the chief financial officer owned 9,401 shares in the company, valued at approximately $421,634.85. This represents a 62.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric J. Loumeau sold 12,500 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $44.86, for a total transaction of $560,750.00. Following the transaction, the insider directly owned 9,088 shares of the company’s stock, valued at $407,687.68. The trade was a 57.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 135,280 shares of company stock worth $6,184,409 over the last ninety days. 33.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AnaptysBio

Several large investors have recently made changes to their positions in ANAB. AQR Capital Management LLC boosted its stake in AnaptysBio by 153.3% during the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after buying an additional 18,165 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of AnaptysBio by 2.7% in the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock valued at $574,000 after purchasing an additional 826 shares in the last quarter. Voya Investment Management LLC bought a new stake in AnaptysBio in the first quarter worth $1,803,000. HighMark Wealth Management LLC raised its stake in AnaptysBio by 58.2% during the second quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock valued at $3,231,000 after purchasing an additional 53,550 shares in the last quarter. Finally, Allianz Asset Management GmbH bought a new position in AnaptysBio during the second quarter valued at $337,000.

AnaptysBio News Roundup

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
• Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
• Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
• Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
• Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.